Drug-drug interactions during antiviral therapy for chronic hepatitis C - Test2 - elhamkhani - TriplyDB

Drug-drug interactions during antiviral therapy for chronic hepatitis C

Drug-drug interactions during antiviral therapy for chronic hepatitis C

http://www.wikidata.org/entity/Q26864887

about

Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective.Chronic hepatitis C: This and the new era of treatment Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance Approved Antiviral Drugs over the Past 50 Years A Review of Daclatasvir Drug-Drug Interactions Drug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy Hepatitis C.Treatment optimization for HIV/HCV co-infected patients.HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Rad51 Interacts with Non-structural 3 Protein of Hepatitis C Virus and Regulates Viral Production Management of hepatitis C in patients with chronic kidney disease.Management of patients with hepatitis C infection and renal disease.Human immunodeficiency virus and liver disease: An update.Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia.Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective Drug combination therapy increases successful drug repositioning.Management of HCV transplant patients with triple therapy.HCV F1/F2 patients: treat now or continue to wait.The current state and future prospects of chronic hepatitis C virus infection treatment.Common GI Drug Interactions in the Elderly.Antiviral drug discovery: broad-spectrum drugs from nature.Drug interactions with new hepatitis C oral drugs.Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection.Drug interactions of hepatitis C direct-acting antivirals in the HIV-infected person.Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology.Safety of direct antiviral agents in the management of hepatitis C.An insight into the molecular characteristics of hepatitis C virus for clinicians.Improving HCV cure rates in HIV-coinfected patients - a real-world perspective.Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.

P2860

Q24564462-D0F2095C-B97A-4783-A0D0-37CA7EDE070E Q26773585-806C75A0-F81F-449C-9499-1AA9B27390F9 Q26775011-C80BB121-B5FA-4A45-BADD-53E30002EBDF Q26781331-3DAA9FB7-B874-4249-AB72-3960D8E628CB Q27755387-6BF6F245-5195-45A4-8EE6-24F387768037 Q28068712-C25575E3-CBE8-4C50-A3BA-1CC8A3258443 Q28069639-AFAA73AC-8FE8-484F-AD10-C5BB6347B5D4 Q28073489-BB64FDC7-716E-4724-AC7C-858F2FF5B84E Q28080752-A820C9DF-244E-4531-B30A-341123594C8A Q28084654-F07B2AC0-2BF3-49CB-8A4C-D21CB93FFBDD Q30235034-11803247-EB6D-4D6D-9C88-6A0FBF5CBAD9 Q31012317-DD44164A-E13D-42F2-B839-E7852EFBC800 Q31168033-106D622E-321B-486C-8B0C-C74D95F42680 Q33426112-2A4209FA-90E6-4728-A4DE-9929E3336DC4 Q33875390-6DD0C5F8-E393-418A-B0B8-2DF5FB6D581D Q34932338-41490F4C-5C63-4F06-B404-5BCDB299F536 Q35127041-97E85C59-4CF3-4B28-914C-B6C3C5466C59 Q36378109-55C4C395-E428-4A7F-AE7D-052024A48CA8 Q36668891-1BD8F429-179E-45FB-AB57-098C8AD02358 Q36690603-5E8F231C-BCEF-457D-86DF-4D9D6371826F Q36870118-5776B571-F447-475F-A482-1A69AF7FB20D Q37004251-A693B259-6A2B-459A-ABC0-C1BC3DFFCA78 Q38174249-2A1BCC06-9E1F-4090-BE4D-B2E1D6187816 Q38174254-DEBF8A8B-5CED-4F37-854B-CA41A4C47A2A Q38217350-7CD0E907-30C4-4341-A80D-AFB1F7D8536B Q38230328-E8E5B6BA-E0F9-417B-9E0E-678EA6A6F323 Q38260235-C727B2B7-F52B-49F2-A857-06138297EC99 Q38305640-D6505237-8830-40D2-B2F8-CB09D9E09856 Q38392453-95F7306C-51A7-408E-BEA1-56930053F5AC Q38544578-97F6E802-B9FB-457B-9807-C48EF16CC13C Q38554604-999FA71C-BCA4-4228-A7AA-5C1F33DF09A7 Q38621245-AB2F9598-E630-441E-94AF-B34951460B5C Q38664453-1D49B2AE-7390-4A13-9B0E-3FBE720F3A6F Q38703524-96F1C2F3-D4FC-45E2-B0AC-4659BB56D33E Q38750141-5B92EB03-1EA9-4865-8BBB-9CC118F613AC Q38818416-9F83C10D-48AA-4169-9EEF-3F54C436EF10 Q38825949-6603241D-A376-4BAA-936C-95511A5F1FBF Q38857697-6EA2D7E5-53F1-4DBC-A0D0-D7842A9B740C Q38927205-AA21A04B-F0B0-4F57-9A2D-C84D351633DA Q38929010-E9080E58-6324-4177-AC06-DFE99194207A

P2860

Drug-drug interactions during antiviral therapy for chronic hepatitis C

http://www.wikidata.org/entity/Q26864887

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Drug-drug interactions during antiviral therapy for chronic hepatitis C

@ast

Drug-drug interactions during antiviral therapy for chronic hepatitis C

@en

Drug-drug interactions during antiviral therapy for chronic hepatitis C

@nl

type

label

Drug-drug interactions during antiviral therapy for chronic hepatitis C

@ast

Drug-drug interactions during antiviral therapy for chronic hepatitis C

@en

Drug-drug interactions during antiviral therapy for chronic hepatitis C

@nl

prefLabel

Drug-drug interactions during antiviral therapy for chronic hepatitis C

@ast

Drug-drug interactions during antiviral therapy for chronic hepatitis C

@en

Drug-drug interactions during antiviral therapy for chronic hepatitis C

@nl

P1433

Q26864887-43882D87-6B77-4FBC-BFB7-488CFC070096

P1476

Q26864887-40E42665-660C-4103-B91E-7E0725356BB1

P2093

Q26864887-2D7BC5BB-C8E8-459D-AD6F-8B1BD28C7003

Q26864887-76AE4C24-A792-490F-94E1-AE38C243AF62

Q26864887-B6D43726-4A70-4FF7-874A-7C71E6A78950

P2860

Q26864887-07DC6D40-F8FB-4933-BF4D-63505F32A36D

Q26864887-1241FA47-520B-47E8-A3C4-3C8E4C941D02

Q26864887-124239A7-5DA4-4312-9CD9-5FF49DAEB65B

Q26864887-173B87FA-E4FC-4DC9-A4A7-53951D699D8E

Q26864887-1BB60895-1DE4-4E7E-9D63-F63B376CC152

Q26864887-2038E058-03E0-4449-8376-A31347A53D4C

Q26864887-2B4DAE64-6D23-4BD0-90B1-E2DDE7EEA40A

Q26864887-31F34165-2590-4A6F-9A03-74EB0D70F940

Q26864887-320B6AD0-330D-4537-8F7F-6A9898002D2C

Q26864887-339DEF0F-A14D-42D3-AF87-6CD03137A818

P2888

Q26864887-E1BC779B-32A7-4D35-ADF8-DC637638346E

P304

Q26864887-C7D8A6E9-B04F-412B-8098-3E98D3D08FD5

P31

Q26864887-8A29E987-E51C-4390-A019-BD61303B75C9

P3181

Q26864887-45CB79D9-E43E-4043-B6B4-918925F74998

P356

Q26864887-8092B84E-506F-4F45-82F9-A59E80C63AE3

P407

Q26864887-16D350E9-E90F-4DE1-87CA-CB0FE7A18C4E

P433

Q26864887-0DAB1E7E-168E-42EE-8055-187831435A25

P478

Q26864887-B69965A0-BE28-41B0-A9DC-133C682B7BC0

P577

Q26864887-3CE45F37-F6D2-48FA-A0C7-B8EC8FD395D4

P6179

Q26864887-D631EBB2-71F5-41EC-887F-75E89015F50A

P698

Q26864887-7D4CE925-5F5A-4740-9104-871F8E36E279

P921

Q26864887-80c5e7b8-4570-2c52-c13c-a32046e20ee7

P932

Q26864887-422FDD8B-E3BE-4F43-9805-9DDC527C4FE5

P3181

P356

NRGASTRO.2013.106

P1433

Nature Reviews Gastroenterology & Hepatology

P1476

Drug-drug interactions during antiviral therapy for chronic hepatitis C

@en

P2093

Gregory T. Everson

http://www.w3.org/2001/XMLSchema#string

James R. Burton

http://www.w3.org/2001/XMLSchema#string

Jennifer J. Kiser

http://www.w3.org/2001/XMLSchema#string

P2860

Boceprevir for previously treated chronic HCV genotype 1 infection

Review and management of drug interactions with boceprevir and telaprevir

Opioid metabolism

Telaprevir for retreatment of HCV infection

Telaprevir for previously untreated chronic hepatitis C virus infection

Boceprevir for untreated chronic HCV genotype 1 infection

Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.

Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.

The effect of garlic supplements on the pharmacokinetics of saquinavir.

Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.

P2888

nrgastro.2013.106

P304

596-606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1953200

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NRGASTRO.2013.106

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1011607603

http://www.w3.org/2001/XMLSchema#string

P698

23817323

http://www.w3.org/2001/XMLSchema#string

P921

P932

4634866

http://www.w3.org/2001/XMLSchema#string